Search Results 481-490 of 18364 for alopecia

1. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

   ... alopecia and other non-clinically significant adverse events (AEs); Patients with no known brain metastasis at baseline must have baseline brain imaging ...

2. Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. Known immediate or delayed ...

3. Publications - Uma Thanarajasingam, M.D., Ph.D. - Mayo Clinic

   Extensive scarring alopecia and widespread rash. J Fam Pract. 2022 Mar; 71 (2):E13-E15 View PubMed; Castillo RM, Sandefur BJ, Finch AS, Richter MD ...

4. ALPN-202 With PD-1 Inhibition in Advanced Malignancies - Mayo Clinic

   Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing ...

5. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305) - Mayo Clinic

   * Toxicities attributed to prior anti-cancer therapy resolved to grade ≤ 1, unless otherwise specified, excluding alopecia or fatigue. * Adequate organ ...

6. A Study to Compare the Effectiveness and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) - Mayo Clinic

   Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 peripheral neuropathy. Exclusion ...

7. Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. An untreated tumor growth ...

8. Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 - Mayo Clinic

   Significant autoimmune disease with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were ...

9. Phase I Study Of BL0020, A Novel Anti-tumor Drug, In Adult Subjects With Advanced Solid Tumors - Mayo Clinic

   ... alopecia) have not been recovered. 20. Patients who are taking anticoagulant therapy (prophylactic use of low-dose aspirin \[≤ 100 mg/day\] or low ...

10. Psoriasis - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...